



Below is a list of notable Mallinckrodt employees who held important roles in the company's leadership, marketing, compliance, sales and government affairs.

<u>Steven Becker</u>, National Account Manager (2000-2014); see other <u>documents</u> authored by Steven Becker

Managed relationships with wholesale distributors and pharmacy chains for generic Mallinckrodt products. Reported to <u>Jane Williams.</u>

<u>Victor Borelli</u>, National Sales Manager (2006?-2012); see other <u>documents</u> authored by Victor Borelli

Customer service liaison between Mallinckrodt and wholesale distributor clients, managing supply and back orders, forecasting sales and other responsibilities. Borelli's emails feature prominently in news coverage of Mallinckrodt lawsuits. Reported to <u>Jane Williams.</u>

<u>Deanna Stacy Chick</u>, Vice President of Specialty Sales (2013-2015); see also <u>Chick emails</u> Succeeded Ron Wickline as leader of Mallinckrodt's specialty sales division. Led its sales efforts

for Mallinckrodt brands like Xartemis for about two years before the division was dissolved.

<u>Ginger Collier</u>, Senior Director of Marketing, Specialty Generics (2009-2015); see also <u>Collier emails</u>

Oversaw marketing plans, promotional literature, product messaging and other marketing efforts for Mallinckrodt's generic products.

<u>John Gillies</u>, Vice President, Global Security (2012-2019); see other <u>documents</u> referencing John Gillies

Led Mallinckrodt's controlled substances compliance group; member of team monitoring suspicious orders. Retired from 29-year career with the FBI, including work with prescription drug investigations, before joining Mallinckrodt.

<u>Matthew Harbaugh</u>, President and CEO of Specialty Generics, previously Executive Vice President and CFO of Mallinckrodt (2007-2019); see other <u>documents</u> referencing and/or related to Matthew Harbaugh

Started with Covidien Pharmaceuticals as VP in imaging solutions group, then promoted to CFO for global finance and shared services, before taking leadership of Generics. Led company's transition away from imaging business and toward pharmaceuticals, including the acquisition of <u>Exalgo</u>, <u>Xartemis</u> and <u>Roxicodone</u>, and the spinoff of Covidien Pharmaceuticals into Mallinckrodt PLC.

Karen Harper, Senior Manager, Controlled Substances Compliance (1975-2019?); see also <u>documents</u> authored by Karen Harper

Started at Mallinckrodt as clerical typist and moved up through compliance group, with a career stretching over 40 years. Led suspicious order monitoring program and responded to reports of theft and diversion; worked with distributor audits and chargeback reports.

<u>Kate (Muhlenkamp) Neely</u>, Product Manager (2007-2011); see other <u>documents</u> referencing and/or related to Kate Neely

Began as marketing analyst for generics; promoted to product manager and led teams for specific <u>"product families,"</u> including oxycodone. Created forecasting tools and worked with supply chain to have inventory on hand. Reported to <u>Ginger Collier</u>.

<u>Bonnie New</u>, National Account Manager (1989-2018); see other <u>documents</u> authored by Bonnie New

Started at Tyco (which bought Mallinckrodt in 2000) in nuclear medicine division, worked in various departments before joining Mallinckrodt pharmaceutical marketing and sales team. Managed relationships with wholesale distributors and pharmacy chains for generic Mallinckrodt products. Reported to <u>Jane Williams.</u>

<u>Hugh O'Neill</u>, Executive Vice President, Chief Commercial Officer (2013-present); see other <u>documents</u> referencing and/or related to Hugh O'Neill

Started as senior vice president for Specialty Generics and was promoted into several leadership roles before becoming CCO. Directs Specialty Brands products, manages commercialization efforts and oversees new product launch execution.

<u>William (Bill, Floyd) Ratliff</u>, Chief Security Officer (2000-2012); see other <u>documents</u> referencing William Ratliff

Went to pharmacies in Florida identified as possible diversion problems and gave reports to DEA and Mallinckrodt. An FBI special agent investigating bank robberies, extortions and drug cases (not involving prescription opioids) before joining Mallinckrodt.

<u>Terrence Terifay</u>, Vice President, General Management/Marketing (2011-2014); see also Terifay <u>emails</u>

Led marketing for Mallinckrodt's branded products; was interim general manager of the brands division. Worked at <u>Synchrony</u> on Mallinckrodt account before joining Mallinckrodt, consulting on <u>Exalgo</u> and Pennsaid risk evaluation mitigation strategy. Had worked with other pharmaceutical companies and their opioid products, including Johnson & Johnson, Purdue and Cephalon.

<u>Mark Trudeau</u>, President and CEO (2012-present); see other <u>documents</u> referencing and/or relating to Mark Trudeau

Employed first by Covidien as senior vice president and president of its pharmaceuticals business, then became Mallinckrodt president and chief executive and a director in 2013, leading the spinoff transition. Served as president and CEO of Bayer HealthCare Pharmaceuticals for a year before joining Mallinckrodt.

<u>Kevin Vorderstrasse</u>, Senior Director, Product Management and Analytics, Specialty Generics (1994-2022); see <u>documents</u> authored by Kevin Vorderstrasse

Developed product management and market analysis team, after holding positions in strategic marketing, product management, market research and quality assurance.

<u>Kevin Webb</u>, Senior Product Manager (2007-2009); Director of Advocacy and Stakeholder Engagement (2013-2016); see <u>documents</u> authored by Kevin Webb

Led strategic development and implementation of company's advocacy initiative, with the goal of making Mallinckrodt a leader in "the pain space." Represented Mallinckrodt with advocacy groups, promoting company's policy of access to appropriate pain management. Promoted programs like the <u>C.A.R.E.S. Alliance</u>, Mallinckrodt's response to diversion, work toward abuse-deterrent technology and more.

<u>Ron Wickline</u>, Vice President, Sales (2010-2014); see other <u>documents</u> referencing and/or related to Ron Wickline

Led Sales division for branded products such as <u>Exalgo</u>, building up sales team through transition from Covidien to Mallinckrodt.

<u>Jane Williams</u>, Vice President, Retail Sales, Specialty Generics (2010-2015); see other <u>documents</u> authored by Jane Williams

Began at Mallinckrodt supervising the generics account managers (including Becker, Borelli and New). Added responsibilities in 2013, then supervising account managers in health system, government sales, inside sales and addiction treatment sales. Stepped down in 2015 at request of supervisor Walt Kaczmarek.